usually appears on the 2 nd -3 rd day, peaking between the 5 th and 7 th days of life. Jaundice may appear at birth or may appear any time during neonatal period depending on the cause. [2] Since we know, hyperbilirubinemia has deleterious effects on neonates such as kernicterus, Choreoathetoid type of cerebral palsy, hearing impairment, and cognitive impairment if not treated at the time. Hence, meticulous screening of newborns is required to detect hyperbilirubinemia. Since the peak bilirubin level typically occurs at 72-96 h, after healthy newborns are discharged from their birth hospital, follow-up is essential. Infants discharged before 72 h should be seen within the next 2 days. Infants at lower gestational ages or who have other risk factors should be seen earlier. [2] This is practically impossible in underdeveloped and even in developing nations because of poverty, low education, and cultural practice. Early discharge of healthy term newborns after delivery has become a common practice because of medical and social reasons and economic constraints. [3] Thus, the recognition, follow-up, and early treatment of jaundice have become more difficult as a result of early discharge from the hospital. Severe jaundice and even kernicterus can occur in some full-term healthy newborns discharged early with no apparent early findings of hemolysis. [4] 
mAteriAls And methods
This prospective hospital-based study was conducted in the Department of Paediatrics and Neonatology, World College of Medical Sciences (WCMS), Jhajjar, Haryana, from January 17, 2016, to December 30, 2018. A total of 289 newborns, fulfilling the predefined inclusion criteria, delivered in our hospital were studied. Proper ethical and scientific clearance was taken from the concerned hospital department. Proper consent was taken from parents of babies after explaining the risks and benefits of neonatal jaundice, phototherapy, and blood sampling.
Inclusion criteria
The inclusion criteria of this study were as follows: a. Gestational age 35 weeks and above (based on last menstrual period) b. The absence of major congenital malformations c. Residing at Jhajjar or nearby whose parents agree to come for follow-up d. Exclusive breastfed babies.
Exclusion criteria
The exclusion criteria of this study were as follows: a. Presence of significant illness (i.e., sepsis and hypothyroidism) b. Rh incompatibility c. ABO incompatibility d. Newborns with obvious life-threatening congenital malformation (tracheoesophageal fistula and anorectal malformation) e. Babies with conjugated hyperbilirubinemia.
All babies delivered in WCMS were examined, and a detailed antenatal and postnatal history was taken. Cases were selected if they fulfilled all the criteria set out above. Informed consent was taken from the parents, and blood was collected from cord blood at birth. Blood sample of the mother was simultaneously collected and sent for blood grouping if it was not known from before. The cord blood sample of the infant was sent for grouping and total serum bilirubin estimation, and then, all babies were examined by senior registrars and experts for clinical assessment of bilirubin as per Kramer's scale and by transcutaneous bilirubinometer for continuous 5 days. Babies were divided into two groups: Group A developing jaundice within physiological range and Group B developing jaundice which needs treatment (pathological jaundice). Babies suspected of having high bilirubin were cross-checked by serum bilirubin level and admitted for treatment if needed as per American academy of pediatrics (AAP) nomogram for hyperbilirubinemia management. Remaining babies were checked for serum bilirubin on the 5 th day of life.
Bilirubin estimation
The serum bilirubin was estimated by microbilirubin (Jendrassik and Grof method) for that venous blood is taken in four microcapillaries and centrifuged at the rate of 10000 rpm for 5 min. Bilirubin estimation is done spectrophotometrically using beam method (55-nm wavelength) (micro la-300, Merck, The Netherlands).
Statistical analysis
Data analysis was carried out using Microsoft Excel sheet.
In case of quantitative data, mean and standard deviation, as well as range (minimum and maximum value), is computed. Sensitivity, specificity, positive predictive value, and negative predictive value of different cut-points of cord blood serum bilirubin were derived. For determining the significance of each test, P < 0.05 was used.
results
Out of 300 newborns enrolled, 11 could not be included in the study because of refusal of consent, drop in follow-up, Rh/ABO incompatibility, and admission in neonatal intensive care unit because of cause other than hyperbilirubinemia. A total of 289 newborns were followed up for the first 5 days of life with clinical assessment and laboratory investigations. Of the enrolled newborns, 169 (58.48%) were male and 120 (41.52%) were female with mean cord blood bilirubin (CBB) and serum bilirubin during evaluation up to 5 days of 2.6 ± 0.8 and 13.9 ± 2.4 and 2.5 ± 0.4 and 12.9 ± 1.8, respectively, with P = 0.89, thus no statistical significance [ Table 1 ].
In our study, 208 (71.179%) babies were >37 weeks of age and 81 (28.03%) were 35-37 weeks' babies. In our study 34 babies developed pathological jaundice, nine babies fall in 35-37 weeks and 25 in >37 weeks age group. Gestational age has no impact when comparison of cord blood bilirubin and mean serum bilirubin of neonates up to 5th day was done (P value=0.95). Similarly, birth weight and mode of delivery comparison of CBB and serum bilirubin when estimated up to the 5 th day has no statistical significance with P = 0.78 and 0.999, respectively, as depicted in Table 1 .
A total of 255 newborns (84.5%) (Group A) developed jaundice which was in physiological range so went home without any treatment. The mean (±standard deviation [SD]) serum TB in cord blood and on day 5 of the babies in this group was 1.6 (±0.4) mg/dl and 11.9(±2.4) mg/dl, respectively [ Table 2 ]. Statistical correlation revealed no significance with P = 0.087.
Total 34 (11.76%) (Group B) infants developed hyperbilirubinemia up to the 5 th day with mean CBB of 2.6 mg/dl with standard deviation of 0.8 mg/dl and mean serum bilirubin (when estimated up to the 5 th day of life) of 16.7 mg/dl with standard deviation of 1.8 and P = 0.0001 [ Table 2 ]. 
discussion
Jaundice is a common entity which needs attention up to some days of birth. Most of the jaundice which develops in healthy newborns is in physiological range except some 8%-10% healthy newborns who develop jaundice which is out of physiological range and needs interventions such as phototherapy, exchange transfusion, or new modalities of treatment. Thus, timely diagnosis and immediate treatment is essential because it could have a devastating effect on their future life because of kernicterus, which leads to mental retardation, choreoathetoid type of cerebral palsy, or hearing defect. Because of increased medical facility and public awareness about side effects of pathological neonatal hyperbilirubinemia, above mentioned sideeffects are less common nowadays. However, still, there is small fraction of newborns who fall prey to the devastating side effects of neonatal hyperbilirubinemia, especially in a developing country, because of poor follow-up, limited resources, and most important parental emotional attachment, who did not want their child to get hurt even from a single needle prick. Keeping in view all these factors, the objective of this research was framed. Our study presumption was that a high serum bilirubin level at birth would also predict a high peak later in life.
Incidence of pathological hyperbilirubinemia in our study was 11.2%, which is in accordance to studies conducted by other authors such as 12.80% in a study by Awasthi and Rehman, [5] 12.00% as per a study by Randev and Grover, [6] and 11.4% in a study by Dhanwadkar et al. [7] In our study, there was no relation between CBB and bilirubin monitored up to the 5 th day of life when gender, gestational age, birth weight, and mode of delivery were compared. Similar findings were noted by Awasthi and Rehman, [5] 1998, and Alpay et al., [8] 2000.
In our study, mean CBB of those babies who developed pathological jaundice was 2.6 ± 0.6 mg/dl (mean ± SD). This finding was in accordance with the research of Knüpfer et al. [9] and Bernaldo and Segre [10] who investigated the predictability of umbilical cord blood unconjugated bilirubin concentration on subsequent hyperbilirubinemia and need for therapy. Utilizing a cutoff point of unconjugated bilirubin of 2.0 mg/dl, they showed that 53% of babies needed phototherapy, and raising the cutoff value to 2.5 mg/dl, they predicted that 72% of babies need phototherapy. Nahar et al., [11] 2009, found CBB of 2.5 mg/dl ± 0.5 which can predict the occurrence of pathological jaundice in neonates.
The present study revealed at CBB level of <2.5 mg/dl, sensitivity of 8.82%, specificity of 83.92%, and positive predictive value and negative predictive value of 6.82% and 87.35%, respectively. Thus, at cord blood <2.5 mg/dl, chances of not developing hyperbilirubinemia are 83.92%. This finding was supported by Rosenfeld [12] who found 4% incidence of neonatal hyperbilirubinemia at CBB level of <2 mg/dl with specificity of 98.23%. Knüpfer et al. [9] derived the incidence of just 0.30% at serum bilirubin level of 1.17-1.75 mg/dl. Other findings which we extracted from our study were sensitivity, specificity, positive predictive value, and negative predictive value at cord blood serum bilirubin level of 2.5-3 mg/dl and >3 mg/dl, and other studies which support this are shown in Table 4 .
As illustrated in Table 4 , our study predicts with high probability at serum bilirubin level >3 mg/dl, and chances of developing pathological neonatal hyperbilirubinemia are very high. Thus, these newborns must be meticulously checked on follow-up. CBB level of 2.5-3.5 also showed good specificity, but due to decreased sensitivity, these newborns can be categorized into intermediate risk. Hence, our study can classify newborns into three risk categories as per cord blood serum bilirubin. [14] >2.35 >15 13 99 85 72 Nahar et al. [11] ≥2.5 ≥17 77 98.6 96 Sun et al. [15] >2 ≥17 68 45.08 Satrya et al. [16] ≥2.54 ≥12.9 90.5 85 STB: Serum total bilirubin be followed more frequently to reduce morbidity and mortality due to neonatal hyperbilirubinemia.
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